Gene Therapy Market - Global Gene Therapy Market Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - (By Vector Coverage, By Indication Coverage, By Delivery Method Type Coverage, By Sales Channel Coverage, By Geogra

Gene Therapy Market - Global Gene Therapy Market Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - (By Vector Coverage, By Indication Coverage, By Delivery Method Type Coverage, By Sales Channel Coverage, By Geographic Coverage and By Company)

The global gene therapy market is on the brink of a revolutionary transformation, with a projected Compound Annual Growth Rate (CAGR) of 19.6% between 2023 and 2030, according to the latest market research report by Fairfield Market Research. The market is set to surge from a value of $7.8 billion in 2022 to a staggering $27.3 billion by 2030, driven by groundbreaking advancements in genetic research and technology.

Advancements in Genetic Research Drive Market Growth

A key catalyst propelling this remarkable growth is the continuous evolution of genetic research and technology, including the game-changing CRISPR-Cas9 and other gene editing tools. These innovations have significantly deepened our understanding of genes and their pivotal role in various diseases, paving the way for innovative therapies.

Surging Incidence of Genetic Disorders Fuels Market Expansion

Another major driver of market growth is the rising incidence of genetic disorders, both congenital and acquired. This surge in genetic ailments has spurred the development and adoption of gene therapy as a promising and viable treatment option, offering hope to patients and healthcare providers alike.

Viral Vectors Dominate the Market

In 2022, the viral vectors category dominated the gene therapy industry. Viral vectors, including adeno-associated virus (AAV) vectors, lentiviral vectors, and retroviral vectors, have historically been the go-to tools in gene therapy due to their efficiency in delivering genetic material into target cells. Among these, adeno-associated virus (AAV) vectors have gained prominence for their safety profile and effectiveness in gene delivery.

Cancer Segment Takes the Lead

In terms of market share, the cancer segment is expected to lead the gene therapy market. The high prevalence of cancer cases worldwide and the potential of gene therapy to offer innovative and effective treatments have driven significant attention toward gene therapies for various types of cancers. Advancements in gene-based cancer therapies, including CAR-T cell therapy and oncolytic viral therapies, have shown promising results in clinical trials and have even been approved for certain cancer types.

In Vivo Gene Therapy Gains Prominence

In 2022, the in vivo category was at the forefront of the market. In vivo gene therapy offers targeted and precise treatments directly within the patient's physiological environment. This approach is easier to administer and has the potential for efficient therapeutic action. In vivo gene therapies find applications across a wide range of diseases, including genetic disorders, various types of cancers, cardiovascular diseases, and neurological disorders.

Neurological Diseases on the Rise

Neurological diseases represent a significant category in the gene therapy market. These disorders encompass a broad spectrum of conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves. Conditions such as Parkinson's disease, Alzheimer's disease, spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), and various forms of ataxia fall within this category.

North America Leads in Innovation and Investment

North America is poised to account for the largest share of the global gene therapy market, driven by its robust technological infrastructure and economic conditions. Renowned research institutions, academic centers, and biotech companies in North America are at the forefront of groundbreaking research and innovation in gene therapy. The region frequently serves as the epicenter for pioneering gene therapies, attracting substantial investments and fostering collaboration.

Asia Pacific Rises on the Global Stage

The gene therapy market is rapidly expanding in the Asia Pacific region, driven by rapid economic growth and technological advancements. Increased healthcare expenditure and research funding, fueled by rising disposable incomes, provide ample resources for research, development, and the adoption of cutting-edge technologies like gene therapy.

Challenges and Regulatory Impact

Despite its remarkable growth prospects, the gene therapy market faces challenges, including prohibitive costs associated with research, development, and manufacturing, as well as the lack of long-term data and follow-up studies to ensure safety and efficacy.

Regulatory Environment Shapes the Industry

Over the past three years, the regulatory environment has played a pivotal role in shaping the gene therapy market. Regulatory bodies, such as the US FDA and the European Medicines Agency (EMA), oversee the safety, efficacy, and quality of gene therapies, and their guidelines and approval processes significantly influence research, development, and market access. Expedited pathways and flexible frameworks have been introduced to accelerate approvals, particularly for treatments addressing rare, life-threatening diseases.

Leaders in the Global Gene Therapy Space

The global gene therapy market is characterized by a consolidated landscape, with a few major players dominating the industry. Leading companies include:

1. Merck KGaA
2. Novartis AG
3. AstraZeneca Plc.
4. BIOCAD
5. Crinetics Pharmaceuticals Inc.
6. EffRx Pharmaceuticals S.A.
7. Euroscreen S.A.
8. Vicore Pharma AB
9. Amgen
10. Bristol-Myers Squibb
11. Cell Genesys Inc.
12. Adaptimmune Therapeutics plc.
13. Achieve Life Science Inc.
14. BioCanCell Ltd.
15. Genelux Corporation
16. Advantagene Inc.
17. GenVec Inc
18. GlaxoSmithKline PLC

Global Gene Therapy Market is Segmented as Below:

By Vector:
• Grade Non-viral Vectors
Oligonucleotides
Other Non-viral Vectors
• Viral Vectors
Retro Viral Vectors
Adeno-associated Virus Vectors
Others Viral Vectors

By Indication:
• Neurological Diseases
• Cancer
• DMD (Duchenne Muscular Dystrophy)
• Hepatological Diseases
• Other Indications

By Delivery Method:
• In Vivo
• Ex Vivo

By Sales Channel:
• Offline Sales Channel
Supermarkets/Hypermarkets
Departmental Stores
Convenience Store
Other Sales Channel
• Online Sales Channel
Company Website
E-commerce Platform

By Geographic Coverage:
• North America
U.S.
Canada
• Europe
Germany
U.K.
France
Italy
Turkey
Russia
Rest of Europe
• Asia Pacific
China
Japan
South Korea
India
Southeast Asia
Rest of Asia Pacific
• Latin America
Brazil
Mexico
Argentina
Rest of Latin America
• Middle East & Africa
GCC
South Africa
Egypt
Nigeria
Rest of the Middle East & Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.